Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.

J. H. Lipton; P. Bryden; M. K. Sidhu; H. Huang; L. J. McGarry; S. Lustgarten; S. Mealing; B. Woods; J. Whelan; N. Hawkins

doi:10.1016/j.leukres.2014.10.005

Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.

J. H. Lipton, P. Bryden, M. K. Sidhu, H. Huang, L. J. McGarry, S. Lustgarten, S. Mealing, B. Woods, J. Whelan, N. Hawkins

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52–68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.

Original language	English
Pages (from-to)	58-64
Number of pages	7
Journal	Leukemia research
Volume	39
Issue number	1
Early online date	1 Nov 2014
DOIs	https://doi.org/10.1016/j.leukres.2014.10.005
Publication status	Published - Jan 2015

Keywords

CML
Ponatinib
Second-generation tyrosine kinase inhibitor
Response
Systematic review

Access to Document

10.1016/j.leukres.2014.10.005

Cite this

Lipton, J. H., Bryden, P., Sidhu, M. K., Huang, H., McGarry, L. J., Lustgarten, S., Mealing, S., Woods, B., Whelan, J., & Hawkins, N. (2015). Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leukemia research, 39(1), 58-64. https://doi.org/10.1016/j.leukres.2014.10.005

@article{8fab7df730794882a45c80efbbcf2590,

title = "Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.",

abstract = "We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52–68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.",

keywords = "CML, Ponatinib, Second-generation tyrosine kinase inhibitor, Response, Systematic review",

author = "Lipton, {J. H.} and P. Bryden and Sidhu, {M. K.} and H. Huang and McGarry, {L. J.} and S. Lustgarten and S. Mealing and B. Woods and J. Whelan and N. Hawkins",

year = "2015",

month = jan,

doi = "10.1016/j.leukres.2014.10.005",

language = "English",

volume = "39",

pages = "58--64",

journal = "Leukemia research",

issn = "0145-2126",

publisher = "Elsevier",

number = "1",

}

Lipton, JH, Bryden, P, Sidhu, MK, Huang, H, McGarry, LJ, Lustgarten, S, Mealing, S, Woods, B, Whelan, J & Hawkins, N 2015, 'Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.', Leukemia research, vol. 39, no. 1, pp. 58-64. https://doi.org/10.1016/j.leukres.2014.10.005

Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. / Lipton, J. H.; Bryden, P.; Sidhu, M. K. et al.
In: Leukemia research, Vol. 39, No. 1, 01.2015, p. 58-64.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.

AU - Lipton, J. H.

AU - Bryden, P.

AU - Sidhu, M. K.

AU - Huang, H.

AU - McGarry, L. J.

AU - Lustgarten, S.

AU - Mealing, S.

AU - Woods, B.

AU - Whelan, J.

AU - Hawkins, N.

PY - 2015/1

Y1 - 2015/1

N2 - We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52–68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.

AB - We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52–68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.

KW - CML

KW - Ponatinib

KW - Second-generation tyrosine kinase inhibitor

KW - Response

KW - Systematic review

U2 - 10.1016/j.leukres.2014.10.005

DO - 10.1016/j.leukres.2014.10.005

M3 - Article

SN - 0145-2126

VL - 39

SP - 58

EP - 64

JO - Leukemia research

JF - Leukemia research

IS - 1

ER -